22157.jpg
Global Multiple Sclerosis Drugs Market Report 2021: Market is Expected to Reach $25.95 Billion in 2025 - Long-term Forecast to 2030
December 13, 2021 06:53 ET | Research and Markets
Dublin, Dec. 13, 2021 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. ...
22157.jpg
Hepatitis Therapeutics Market - Global Forecast to 2027
December 10, 2021 03:03 ET | Research and Markets
Dublin, Dec. 10, 2021 (GLOBE NEWSWIRE) -- The "Hepatitis Therapeutics Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Other Types), Drug Class (Interferon, Monoclonal...
MPN Research Foundation
3-Year Global MPN Interferon Initiative Report Released by MPN Research Foundation
November 01, 2021 08:45 ET | MPN Research Foundation
Chicago, IL, Nov. 01, 2021 (GLOBE NEWSWIRE) -- In real-world usage and in clinical trials, interferon (IFN) in a variety of forms has shown high rates of hematologic and molecular responses in many...
22157.jpg
Global $8.74 Billion Interferons (IFN Alpha, Beta, Gamma) Markets, 2015-2020, 2020-2025F, 2030F
May 28, 2021 04:53 ET | Research and Markets
Dublin, May 28, 2021 (GLOBE NEWSWIRE) -- The "Interferons Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major...
BetterLife New Logo.png
BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003
March 11, 2021 08:00 ET | BetterLife Pharma
VANCOUVER, March 11, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), today announced that its wholly-owned subsidiary, Altum...
22157.jpg
Global Autoimmune Disease Therapeutics Market (2021 to 2025) - Size & Forecast with Impact Analysis of COVID-19
February 23, 2021 08:43 ET | Research and Markets
Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Autoimmune Disease Therapeutics Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to...
BetterLife New Logo.png
BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases
January 26, 2021 08:30 ET | BetterLife Pharma
VANCOUVER, Jan. 26, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and...
BetterLife New Logo.png
BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia
January 21, 2021 08:30 ET | BetterLife Pharma
VANCOUVER, Jan. 21, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and...
22157.jpg
Global Multiple Sclerosis Therapies Report 2020-2025
December 08, 2020 08:53 ET | Research and Markets
Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
What do the Pfizer Vaccine and BetterLife Pharma have in common?
November 18, 2020 07:30 ET | BetterLife Pharma
New York City, Nov. 18, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotech company focused on development and...